This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Serum prostaglandin E2
Timeframe: Change between Visit 3 (10 days post surgery) and Visit 6 (1 year post surgery)
T1rho relaxation time on MRI
Timeframe: Change between Visit 4 (4 weeks post surgery) and Visit 6 (1 year post surgery)
Shape of the medial femoral condyle on MRI
Timeframe: Change between Visit 4 (4 weeks post surgery) and Visit 6 (1 year post surgery)
Knee injury and Osteoarthritis Outcome Score (KOOS)
Timeframe: Change between Visit 3 (10 days post surgery) and Visit 6 (1 year post surgery)